Join industry expert Dan O’Leary on Feb. 23 when he’ll identify the most frequently cited steps in the corrective and preventive action processes, explain the issues that warning letters reveal and provide information to avoid these problems.
(PRWeb February 17, 2017)
Read the full story at http://www.prweb.com/releases/FDAnews/capamd/prweb14080781.htm
For more information, please visit
http://www.prweb.com/releases/FDAnews/capamd/prweb14080781.htm